[ad_1]
The American pharmaceutical company Moderna released the key research results of its new coronavirus vaccine on the 16, stating that the effective rate is as high as 94.5%, which is higher than the previous Pfizer vaccine.
Although in practice there may be a gap between the effectiveness of the vaccine trial and the actual efficacy, whether it is the Pfizer or Moderna vaccine, it will still be necessary to know the effectiveness after its release, after all, the test itself it will deviate from reality. The current optimism is actually based on the fact that the effectiveness of the first batch of vaccines may only be above 60 to 70%, but this has already excited the market.
Whether Pfizer or Moderna, the working principle of the vaccine is different from common sense: it is not the dilution of the virus to make the immune system produce antibodies automatically, but a genetic vaccine. It contains the unique genetic code fragment of the new coronavirus spike protein and the new coronavirus protein that allows the cell to produce new, harmless coronavirus proteins to produce immune antibodies.
Furthermore, the so-called efficacy data has not undergone strict third-party academic review. Basically, the government publishes them unilaterally. However, experimental results show that after vaccination, the disease can be effectively suppressed. Not all seriously ill patients are vaccinated. The market is quite bullish. In fact, American infectious disease scholar Anthony Fauci believes that as long as the vaccine has a 70-75% attack effect, it is quite good and the government is willing to approve it if it reaches 50% or more.
Current data indicates that both vaccines need to be injected twice with few serious side effects, but the two are not the same. Moderna can cause fatigue, headache, and joint pain. The side effects of Pfizer are similar to those of the flu and can cause fever. After the injection, both companies had symptoms of pain at the injection site. However, even if both vaccines are quickly approved, the first batch of supply will be only 30 million doses at most, it is still impossible to popularize this year.
It is expected that in the second quarter of next year, ordinary people will have the opportunity to get vaccinated, and logistics will be the biggest problem. In this sense, the Moderna vaccine has many advantages over Pfizer. It can be stored in the refrigerator for almost a month and it can be stored for almost half a year at minus 20 degrees Celsius. This is very good news to popularize the vaccine.
(The source of the first image: shutterstock)
Other readings:
New knowledge of science and technology, always updated
[ad_2]
